A novel small inhibitor, LLL12, targets STAT3 in non‑small cell lung cancer in vitro and in vivo

Nie,Yanli; Li,Yuanyuan; Hu,Sheng

doi:10.3892/ol.2018.9262

A novel small inhibitor, LLL12, targets STAT3 in non‑small cell lung cancer in vitro and in vivo

Authors:
- Yanli Nie
- Yuanyuan Li
- Sheng Hu
View Affiliations

Affiliations: Department of Gastrointestinal Medical Oncology, Hubei Province Cancer Hospital, Wuhan, Hubei 430079, P.R. China, College of Chemistry, Central China Normal University, Wuhan, Hubei 430079, P.R. China
Published online on: August 3, 2018 https://doi.org/10.3892/ol.2018.9262
Pages: 5349-5354

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer‑associated mortality worldwide. Despite the development of novel molecular therapies, the prognosis for patients with locally advanced or metastatic lung cancer remains poor. Therefore, the identification of novel therapeutic approaches is required. In numerous types of cancer, the constitutive activation of signal transducer and activator of transcription 3 (STAT3) signaling serves as a potent therapeutic target. The present study aimed to characterize the suppressive role of LLL12, a STAT3 small molecule inhibitor, in lung cancer cell proliferation and tumor growth. The mechanism of STAT3 signaling modulation by LLL12 was also investigated. The antitumor activity of LLL12 was revealed to take place via inhibition of lung cancer cell proliferation and migration in vitro. High and low doses of LLL12 significantly reduced tumor volume and weight in xenograft mice compared with that in the control group. Furthermore, LLL12 was demonstrated to reduce the level of STAT3 phosphorylation. These results suggested that LLL12 inhibited the proliferation and migration of A549 cells, and the increase in tumor volume in nude mice with lung cancer. This may be associated with the inhibitory effect of STAT3 phosphorylation and the expression of STAT3. The results of the present study suggest that constitutive STAT3 signaling is required for lung cancer cell survival and migration, and tumor growth in vivo. It is also indicated that LLL12 has clinical potential as a novel targeted therapy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
3	Reka AK, Goswami MT, Krishnapuram R, Standiford TJ and Keshamouni VG: Molecular cross-regulation between PPAR-γ and other signaling pathways: Implications for lung cancer therapy. Lung Cancer. 72:154–159. 2011. View Article : Google Scholar : PubMed/NCBI
4	Haura EB, Turkson J and Jove R: Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol. 2:315–324. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kamran MZ, Patil P and Gude RP: Role of STAT3 in cancer metastasis and translational advances. BioMed Res Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
6	Jatiani SS, Baker SJ, Silverman LR and Reddy EP: Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies. Genes Cancer. 1:979–993. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yu H and Jove R: The STATs of cancer—new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI
8	Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ and Mackeigan JP: STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PloS One. 7:e308202012. View Article : Google Scholar : PubMed/NCBI
9	Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R and Huang S: Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004. View Article : Google Scholar : PubMed/NCBI
10	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
11	Carpenter RL and Lo HW: STAT3 target genes relevant to human cancers. Cancers (Basel). 6:897–925. 2014. View Article : Google Scholar : PubMed/NCBI
12	Debnath B, Xu S and Neamati N: Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem. 55:6645–6668. 2012. View Article : Google Scholar : PubMed/NCBI
13	Masciocchi D, Gelain A, Villa S, Meneghetti F and Barlocco D: Signal transducer and activator of transcription 3 (STAT3): A promising target for anticancer therapy. Future Med Chem. 3:567–597. 2011. View Article : Google Scholar : PubMed/NCBI
14	Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, et al: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 16:487–497. 2009. View Article : Google Scholar : PubMed/NCBI
15	Sen M, Thomas SM, Kim S, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee J, Sahu N, Joyce S, et al: First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy. Cancer Discov. 2:694–705. 2012. View Article : Google Scholar : PubMed/NCBI
16	Alas S and Bonavida B: Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 9:316–326. 2003.PubMed/NCBI
17	Sledz CA and Williams BR: RNA interference in biology and disease. Blood. 106:787–794. 2005. View Article : Google Scholar : PubMed/NCBI
18	Stein CA: The experimental use of antisense oligonucleotides: A guide for the perplexed. J Clin Invest. 108:641–644. 2001. View Article : Google Scholar : PubMed/NCBI
19	Lin L, Hutzen B, Li PK, Ball S, Zuo M, DeAngelis S, Foust E, Sobo M, Friedman L, Bhasin D, et al: A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia. 12:39–50. 2010. View Article : Google Scholar : PubMed/NCBI
20	Liu A, Liu Y, Li PK, Li C and Lin J: LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells. Anticancer Res. 31:2029–2035. 2011.PubMed/NCBI
21	Zuo M, Li C, Lin J and Javle M: LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy. Oncotarget. 6:10940–10949. 2015. View Article : Google Scholar : PubMed/NCBI
22	Mankan AK and Greten FR: Inhibiting signal transducer and activator of transcription 3: Rationality and rationale design of inhibitors. Exp Opin Investig Drugs. 20:1263–1275. 2011. View Article : Google Scholar
23	Bid HK, Oswald D, Li C, London CA, Lin J and Houghton PJ: Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12. PloS One. 7:e355132012. View Article : Google Scholar : PubMed/NCBI
24	Bishop JL, Thaper D and Zoubeidi A: The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers (Basel). 6:829–859. 2014. View Article : Google Scholar : PubMed/NCBI
25	Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS and Ogino S: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C and Lin J: STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xiong H, Du W, Wang JL, Wang YC, Tang JT, Hong J and Fang JY: Constitutive activation of STAT3 is predictive of poor prognosis in human gastric cancer. J Mol Med(Berl). 90:1037–1046. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ryu K, Choy E, Yang C, Susa M, Hornicek FJ, Mankin H and Duan Z: Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthopaed Res. 28:971–978. 2010.
29	Schoppmann SF, Jesch B, Friedrich J, Jomrich G, Maroske F and Birner P: Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer. Clin Exp Metastasis. 29:615–624. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ball S, Li C, Li PK and Lin J: The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells. PloS One. 6:e188202011. View Article : Google Scholar : PubMed/NCBI
31	Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C and Lin J: A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer. 130:1459–1469. 2012. View Article : Google Scholar : PubMed/NCBI
32	Onimoe GI, Liu A, Lin L, Wei CC, Schwartz EB, Bhasin D, Li C, Fuchs JR, Li PK, Houghton P, et al: Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 30:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
33	Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC and London CA: Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines. BMC Vet Res. 8:2442012. View Article : Google Scholar : PubMed/NCBI